NCT02151526: A reported trial by Genetix Biotherapeutics Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02151526 |
|---|---|
| Title | A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the β-Hemoglobinopathies (Sickle Cell Anemia and β-Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral β-A-T87Q Globin Vector (LentiGlobin BB305 Drug Product) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 7, 2013 |
| Completion date | Feb. 26, 2019 |
| Required reporting date | Feb. 26, 2020, midnight |
| Actual reporting date | Feb. 26, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |